A10 Identifying and targeting escape mechanisms in AML using multispecific antibody derivatives
The major challenge in the treatment of acute myeloid leukemia (AML) is the prevention of relapse due to refractory leukemic stem cells (LSC). The project aims to identify and counteract the evolution of immune resistance of LSCs. We will profile residual and relapsed leukemic cells after allogeneic stem cell transplantation or after antibody therapy to identify resistance mechanisms. Multispecific antibodies will be engineered to simultaneously target LSCs and limit immune escape based on the knowledge of leukemic evolution.
Prof. Dr. Karl-Peter HopfnerGenzentrum, Department Biochemie, Ludwig-maximilians-Universität München +49 (0)89 2180-76953 |
Prof. Dr. Marion SubkleweMedizinische Klinik und Poliklinik III, Ludwig-Maximilians-Universität München Gene Center Munich +49 (0)89 44007-3133 (hospital), +49( 0)89 2180 76875 (lab) |